Abnormal MicroRNA Expression in Ts65Dn Hippocampus and Whole Blood: Contributions to Down Syndrome Phenotypes

Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
Developmental Neuroscience (Impact Factor: 2.7). 11/2011; 33(5):451-67. DOI: 10.1159/000330884
Source: PubMed


Down syndrome (DS; trisomy 21) is one of the most common genetic causes of intellectual disability, which is attributed to triplication of genes located on chromosome 21. Elevated levels of several microRNAs (miRNAs) located on chromosome 21 have been reported in human DS heart and brain tissues. The Ts65Dn mouse model is the most investigated DS model with a triplicated segment of mouse chromosome 16 harboring genes orthologous to those on human chromosome 21. Using ABI TaqMan miRNA arrays, we found a set of miRNAs that were significantly up- or downregulated in the Ts65Dn hippocampus compared to euploid controls. Furthermore, miR-155 and miR-802 showed significant overexpression in the Ts65Dn hippocampus, thereby confirming results of previous studies. Interestingly, miR-155 and miR-802 were also overexpressed in the Ts65Dn whole blood but not in lung tissue. We also found overexpression of the miR-155 precursors, pri- and pre-miR-155 derived from the miR-155 host gene, known as B cell integration cluster, suggesting enhanced biogenesis of miR-155. Bioinformatic analysis revealed that neurodevelopment, differentiation of neuroglia, apoptosis, cell cycle, and signaling pathways including ERK/MAPK, protein kinase C, phosphatidylinositol 3-kinase, m-TOR and calcium signaling are likely targets of these miRNAs. We selected some of these potential gene targets and found downregulation of mRNA encoding Ship1, Mecp2 and Ezh2 in Ts65Dn hippocampus. Interestingly, the miR-155 target gene Ship1 (inositol phosphatase) was also downregulated in Ts65Dn whole blood but not in lung tissue. Our findings provide insights into miRNA-mediated gene regulation in Ts65Dn mice and their potential contribution to impaired hippocampal synaptic plasticity and neurogenesis, as well as hemopoietic abnormalities observed in DS.

Download full-text


Available from: Eric D Lombardini, Jun 24, 2014
  • Source
    • "It is possible that in DS, disomic Gabrb3 is modified by overexpressed trisomic microRNAs (miRNAs) or transcription factors located on Hsa21 [2,3,28,80-82]. The trisomic region of Mmu16 in Ts65Dn mice harbours two of the miRNAs located on Hsa21, mir-155 and mir-802, [2,80,81,83,84] and these are overexpressed in Ts65Dn hippocampus and prefrontal cortex [80]. However, they are not predicted to target human or mouse Gabrb3 mRNAs [85-87]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Down's syndrome (DS) is caused by triplication of all or part of human chromosome 21 and is characterized by a decrease in the overall size of the brain. One of the brain regions most affected is the cerebellum, in which the number of granule cells (GCs) is markedly decreased. GCs process sensory information entering the cerebellum via mossy fibres and pass it on to Purkinje cells and inhibitory interneurons. How GCs transform incoming signals depends on their input--output relationship, which is adjusted by tonically active GABAA receptor channels. We report that in the Ts65Dn mouse model of DS, in which cerebellar volume and GC number are decreased as in DS, the tonic GABAA receptor current in GCs is smaller than in wild-type mice and is less effective in moderating input resistance and raising the minimum current required for action potential firing. We also find that tonically active GABAA receptors curb the height and broaden the width of action potentials in wild-type GCs but not in Ts65Dn GCs. Single-cell real-time quantitative PCR reveals that these electrical differences are accompanied by decreased expression of the gene encoding the GABAA receptor beta3 subunit but not genes coding for some of the other GABAA receptor subunits expressed in GCs (alpha1, alpha6, beta2 and delta). Weaker moderation of excitability and action potential waveform in GCs of the Ts65Dn mouse by tonically active GABAA receptors is likely to contribute to atypical transfer of information through the cerebellum. Similar changes may occur in DS.
    Molecular Brain 07/2013; 6(1):33. DOI:10.1186/1756-6606-6-33 · 4.90 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lipopolysaccharide (LPS) is recognized as the most potent microbial mediator presaging the threat of invasion of Gram-negative bacteria that implicated in the pathogenesis of sepsis and septic shock. This study was designed to examine the microRNA (miRNA) expression in whole blood from mice injected with intraperitoneal LPS. C57BL/6 mice received intraperitoneal injections of varying concentrations (range, 10-1000 μg) of LPS from different bacteria, including Escherichia coli, Klebsiella pneumonia, Pseudomonas aeruginosa, Salmonella enterica, and Serratia marcescens and were killed 2, 6, 24, and 72 h after LPS injection. Whole blood samples were obtained and tissues, including lung, brain, liver, and spleen, were harvested for miRNA expression analysis using an miRNA array (Phalanx miRNA OneArray® 1.0). Upregulated expression of miRNA targets in the whole blood of C57BL/6 and Tlr4(-/-) mice injected with LPS was quantified using real-time RT-PCR and compared with that in the whole blood of C57BL/6 mice injected with lipoteichoic acid (LTA) from Staphylococcus aureus. Following LPS injection, a significant increase of 15 miRNAs was observed in the whole blood. Among them, only 3 miRNAs showed up-regulated expression in the lung, but no miRNAs showed a high expression level in the other examined tissues. Upregulated expression of the miRNA targets (let-7d, miR-15b, miR-16, miR-25, miR-92a, miR-103, miR-107 and miR-451) following LPS injection on real-time RT-PCR was dose- and time-dependent. miRNA induction occurred after 2 h and persisted for at least 6 h. Exposure to LPS from different bacteria did not induce significantly different expression of these miRNA targets. Additionally, significantly lower expression levels of let-7d, miR-25, miR-92a, miR-103, and miR-107 were observed in whole blood of Tlr4(-/-) mice. In contrast, LTA exposure induced moderate expression of miR-451 but not of the other 7 miRNA targets. We identified a specific whole blood-derived miRNA signature in mice exposed to LPS, but not to LTA, from different gram-negative bacteria. These whole blood-derived miRNAs are promising as biomarkers for LPS exposure.
    Journal of Biomedical Science 07/2012; 19(1):69. DOI:10.1186/1423-0127-19-69 · 2.76 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: MicroRNA (miRNAs) play a critical role in tumor pathogenesis either as oncogenes or tumor suppressor genes. However, the role of miRNA and their regulation in response to proteasome inhibitors in multiple myeloma (MM) is unclear. miRNA profiling in proteasome inhibitor MLN2238-treated MM.1S MM cells shows upregulation of miR-33b. Mechanistic study indicates that induction of miR-33b is predominantly via transcriptional regulation. Examination of miR33b in patient MM cells showed a constitutively low expression. Overexpression of miR-33b decreased MM cell viability, migration, colony formation, as well as increased apoptosis and sensitivity of MM cells to MLN2238 treatment. Additionally, overexpression of miR-33b or MLN2238 exposure negatively regulates oncogene PIM-1 and blocks PIM-1-wild-type, but not PIM-1-mutant luciferase activity. Moreover, PIM-1 overexpression led to significant abrogation of miR-33b or MLN2238-induced cell death. SGI-1776, a biochemical inhibitor of PIM-1 triggered apoptosis in MM. Finally, overexpression of miR-33b inhibits tumor growth and prolongs survival in both subcutaneous and disseminated human MM xenograft models. Together, our study suggests that miR-33b is a tumor suppressor, which plays a role during MLN2238-induced apoptotic signaling in MM cells, and these data provide the basis for novel therapeutic strategies targeting miR-33b in MM.
    Blood 09/2012; 120(19). DOI:10.1182/blood-2012-01-401794 · 10.45 Impact Factor
Show more